PD-L1 Antikörper

Produktnummer ABIN6727404

Dieses Anti-PD-L1-Antikörper ist ein Ratte Monoklonal-Antikörper zur Detektion von PD-L1 in FACS. Geeignet für Maus.

Kurzübersicht für PD-L1 Antikörper (ABIN6727404)

Target: PD-L1 (CD274 (PD-L1))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser PD-L1 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS)

Klon: 10F-9G2

Produktdetails anti-PD-L1 Antikörper

Aufreinigung: Purified

Isotyp: IgG2b, kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Kommentare:

Matching Isotype Control: Purified Rat IgG2b, κ Isotype Control (ABIN7469856)

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: PBS with 0.05 % Proclin300

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2~8°C. Do not freeze.

Details zu PD-L1

Target: PD-L1 (CD274 (PD-L1))

Andere Bezeichnung: CD274/PD-L1

Hintergrund: B7-H1, PD-L1,Programmed cell death ligand 1,B7 homolog 1,B7-H, B7H1, PDL1, PDCD1L1, PDCD1LG1,CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Gen-ID: 60533

UniProt: Q9EP73

Pathways: Cancer Immune Checkpoints